Overview

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC

Status:
NOT_YET_RECRUITING

Trial end date:
2029-04-15

Target enrollment:

Participant gender:

Summary

This is an open-label, non-randomized, controlled, single-center, phase II study to compare the efficacy and safety of neoadjuvant PD-L1/PD-1 inhibitor + chemotherapy (carboplatin/cisplatin + etoposide) with chemotherapy (carboplatin/cisplatin + etoposide) alone followed by radical surgery and adjuvant treatment as perioperative therapy in patients with limited-stage SCLC.

Phase:

PHASE2

Details

Lead Sponsor:

Beijing Chest Hospital, Capital Medical University

Treatments:

Carboplatin
Cisplatin
Etoposide
tislelizumab